№ lp_2_1_32862
File format: docx
Character count: 13080
File size: 175 KB
Year:
2023
Region / city:
United States
Topic:
Divorce, Children, Group Therapy
Document Type:
Educational material
Organization / Institution:
Lamar University
Author:
Jennifer Finegan
Target audience:
Adolescents, Educators, Counselors
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Context:
Psychoeducational group program for adolescents to help cope with the effects of divorce.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Contextual Description:
Form used by pest control companies for providing disclosure and treatment details related to wood destroying insects.
Year:
2024
Region / city:
United Kingdom
Topic:
Health technology assessment
Document type:
Appeal hearing report
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
NICE
Target audience:
Healthcare professionals, industry representatives, public
Period of validity:
Not specified
Approval date:
23 September 2024
Date of changes:
Not specified
Year:
2021
Region / City:
United Kingdom
Subject:
Health economics, antimicrobial evaluation
Document type:
Final report
Organization / Institution:
Centre for Health Economics, University of York; Health Economics and Decision Science, University of Sheffield
Author:
Sue Harnan, Ben Kearns, Alison Scope, Laetitia Schmitt, Dina Jankovic, Jean Hamilton, Ruth Wong, Tushar Srivastava, Harry Hill, Chu Chang Ku, Kate Ren, Claire Rothery, Laura Bojke, Mark Sculpher, Beth Woods
Target audience:
Healthcare professionals, policymakers, researchers
Period of validity:
2016 - ongoing
Approval date:
October 2021
Date of last modification:
October 2021
Year:
2013
Region / city:
United Kingdom
Theme:
Psychopharmacology, Depression
Document type:
Guideline
Organization / Institution:
British Association for Psychopharmacology
Author:
A.J. Cleare, C.M. Pariante, A.H. Young, et al.
Target audience:
Healthcare professionals, researchers
Period of validity:
2013 and onwards
Approval date:
September 2012
Date of changes:
2013
Year:
2024
Region / City:
United Kingdom
Topic:
Health Technology Assessment
Document Type:
Appeal Hearing Summary
Organization / Institution:
National Institute for Health and Care Excellence (NICE)
Author:
Dr Biba Stanton, Chair, NICE
Target Audience:
Healthcare professionals, policy makers, stakeholders in healthcare assessments
Period of validity:
Not specified
Date of approval:
Not specified
Date of amendments:
Not specified
Year:
2025
Region / city:
Australia
Theme:
Nursing, Education, Disability Support
Document Type:
Request for Information
Organization / institution:
Mater Education
Author:
Mater Education
Target audience:
Prospective students, treating doctors
Period of validity:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Texas
Topic:
Pest Control, Termite Treatment
Document Type:
Guide
Organization / Institution:
Texas Department of Agriculture
Author:
Texas Department of Agriculture
Target Audience:
Builders, Consumers, Pest Control Operators
Validity Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2014
Region / City:
South Africa
Topic:
Consumer protection, financial sector conduct
Document Type:
Regulatory guidelines
Authority / Institution:
Financial Sector Conduct Authority (FSCA)
Author:
FSCA
Target Audience:
Financial Services Providers (FSPs), Key Individuals, and Representatives
Effective Date:
January 2014
Legislation:
Fit and Proper amendments, FAIS Act, COFI Bill
Date of Changes:
December 2018 (draft COFI Bill)
Year:
2026
Region / City:
United Kingdom
Theme:
Pharmaceutical Treatment
Document Type:
Prescribing Information
Organization:
NHS
Author:
Dr. Joanne Ritchie
Target Audience:
Healthcare professionals, specifically specialists and GPs
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Contraindications:
Venous thromboembolic disorder, arterial thromboembolic disease, known thrombophilic disorders, known osteoporosis, headaches with focal neurological symptoms, pregnancy, breastfeeding
Monitoring:
DEXA scan recommended after 1 year of treatment
Special Warnings/Precautions:
Use of non-hormonal contraception for at least 1 month after initiation
Adverse Effects:
Hot flushes, headache
Primary Care responsibilities for continuation:
Prescribe as recommended, seek advice from the specialist if needed
Specialist Service responsibilities for initiation:
Discuss benefits and side effects with the patient, initiate treatment and monitor
Criteria for Discontinuation:
Menopause, increase in migraine frequency, ATE/VTE events, acute liver deterioration
Date of Initiation:
Not specified
Communication:
Contact details for the specialist and hospital pharmacy provided
Year:
2016
Region / city:
York, UK
Topic:
Gene therapy for ADA-SCID
Document type:
Review article
Organization / institution:
National Institute for Health and Care Excellence (NICE)
Author:
Emily South, Edward Cox, Nick Meader, Nerys Woolacott, Susan Griffin
Target audience:
Healthcare professionals, decision-makers in health technology assessment
Period of validity:
2016
Approval date:
May 2016
Date of changes:
Not specified
Year:
2024
Date of hearing:
24 May 2024
Country:
England
Document type:
Appeal hearing decision summary
Subject:
Olipudase alfa for treating Niemann-Pick disease types AB and B (ASMD)
Institution:
National Institute for Health and Care Excellence
Appeal body:
Highly Specialised Technologies Appeal Panel
Appellant:
Niemann-Pick UK
Legal adviser:
DAC Beachcroft LLP
Grounds of appeal:
Ground 1(a) – failure to act fairly; Ground 2 – unreasonableness in light of the evidence
Technology appraisal identifier:
ID3913
Therapeutic area:
Acid sphingomyelinase deficiency (ASMD)
Target population:
People with ASMD types AB and B in England
Date:
19 March 2024
Organisation:
Niemann-Pick UK (NPUK)
Address:
Suite 2, Vermont House, Concord, Washington NE37 2SQ
Addressee:
Dr Mark Chakravarty, Lead Non-executive Director for Appeals
Institution:
National Institute for Health and Care Excellence
Subject:
Appeal of Final Draft Guidance decision
Technology Appraised:
Olipudase alfa
Indication:
Acid sphingomyelinase deficiency (Niemann-Pick disease) type AB and type B
Reference ID:
ID3913
Grounds for Appeal:
Failure to act fairly; Unreasonable recommendation in light of evidence
Document Type:
Formal appeal letter
Geographical Scope:
United Kingdom
Cited Studies:
Raebel et al., Orphanet Journal of Rare Diseases (2024); Fraser et al.
Year:
2020
Region / city:
New South Wales
Topic:
Antimicrobial resistance, Gonococcal infections, Treatment options
Document type:
Research article
Institution:
World Health Organization Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, Sydney
Author(s):
Benjamin H Armstrong, Athena Limnios, David A Lewis, Tiffany Hogan, Ratan Kundu, Sanghamitra Ray, Masoud Shoushtari, Jasmin El Nasser, Tim Driscoll, Monica M Lahra
Target audience:
Researchers, healthcare professionals, policy makers
Period of validity:
2015-2020
Date of approval:
2020
Date of changes:
Not applicable
Authors:
Brendan J. McMullan; Anita J. Campbell; Christopher C. Blyth; Jonathan C. McNeil; Christopher P. Montgomery; Steven Y. C. Tong; Asha C. Bowen
Type of document:
Narrative review article
Topic:
Pediatric Staphylococcus aureus bacteremia
Population:
Neonates, children and adolescents
Medical specialty:
Infectious Diseases
Methods:
Systematic appraisal of published literature
Data sources:
PubMed and Medline
Search period:
January 1960 – 31 December 2018
Geographic context:
High-income countries
Funding source:
No funding received
Conflict of interest:
None declared
Clinical scope:
Community-acquired and healthcare-associated bacteremia
Year:
2023
Region / City:
Canberra, Australia
Topic:
Paediatric intravenous extravasation management
Document Type:
Guideline
Organization:
Canberra Health Services
Author:
Expert clinical reference groups
Target Audience:
Clinicians in paediatric care
Period of validity:
Ongoing
Approval Date:
7 December 2023
Amendment Date:
26 August 2024
Clinical Commissioning Policy Tenofovir alafenamide for treatment of HIV 1 in adults and adolescents
Year:
2025
Region / City:
England
Theme:
HIV Treatment, Antiretroviral Therapy
Document Type:
Policy Statement
Organization / Institution:
NHS England
Author:
NHS England
Target Audience:
Healthcare professionals, policy makers
Effective Period:
Ongoing from May 2025
Approval Date:
May 2025
Date of Last Update:
August 2025
Year:
2021
Region:
England
Subject:
HIV-1 treatment
Document type:
Clinical commissioning policy
Organization:
NHS England
Target audience:
Adults and adolescents living with HIV-1
Approved date:
2021
Drug reviewed:
Tenofovir alafenamide (TAF)
Treatment context:
Antiretroviral therapy (ART)
Purpose:
Funding and clinical guidance for TAF use
Evidence reviewed:
Comparative safety and efficacy versus TDF
Population:
Patients with contraindications to TDF or with complications during treatment
Year:
2025
Region / City:
Canberra
Topic:
Medical Procedures, Oncology, Hematology
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Author:
Canberra Health Services
Target Audience:
Healthcare professionals involved in chemotherapy administration
Effective Period:
Ongoing
Approval Date:
2025-01-01
Date of Changes:
2025-01-01